SkyOak Wealth LLC Lowers Holdings in Lantheus Holdings, Inc. $LNTH

Posted by on Sep 2nd, 2026

SkyOak Wealth LLC trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 30.9% in the 2nd quarter, Holdings Channel reports. The firm owned 44,419 shares of the medical equipment provider’s stock after selling 19,865 shares during the quarter. SkyOak Wealth LLC’s holdings in Lantheus were worth $4,928,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after purchasing an additional 1,950,252 shares during the period. Jupiter Topco LLC bought a new stake in Lantheus during the second quarter valued at $575,628,000. Reinhart Partners LLC. grew its position in Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after buying an additional 34,501 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Lantheus by 3.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after buying an additional 44,374 shares in the last quarter. Finally, Carmignac Gestion increased its stake in Lantheus by 18.4% in the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock worth $100,729,000 after acquiring an additional 206,000 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Trading Down 0.1%

NASDAQ LNTH opened at $100.88 on Wednesday. The stock’s 50-day simple moving average is $103.53 and its two-hundred day simple moving average is $92.24. Lantheus Holdings, Inc. has a twelve month low of $49.67 and a twelve month high of $111.86. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $6.58 billion, a price-to-earnings ratio of 24.37 and a beta of -0.03.

Lantheus (NASDAQ:LNTH – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The firm had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.57 EPS. Research analysts forecast that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LNTH. Brookline Capital Markets cut Lantheus from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Leerink Partners set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Weiss Ratings raised shares of Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 27th. Finally, William Blair set a $102.50 target price on shares of Lantheus in a research report on Monday, August 3rd. Four analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Hold” and a consensus target price of $108.11.

View Our Latest Analysis on Lantheus

About Lantheus

(Free Report)

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Featured Articles

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.